These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33330054)

  • 1. The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer.
    Poot AJ; Lam MGEH; van Noesel MM
    Front Oncol; 2020; 10():578286. PubMed ID: 33330054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Radioligand Theranostics in Oncology.
    Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
    Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
    Langbein T; Weber WA; Eiber M
    J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
    Burkett BJ; Bartlett DJ; McGarrah PW; Lewis AR; Johnson DR; Berberoğlu K; Pandey MK; Packard AT; Halfdanarson TR; Hruska CB; Johnson GB; Kendi AT
    Radiol Imaging Cancer; 2023 Jul; 5(4):e220157. PubMed ID: 37477566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic approaches in nuclear medicine: current status and future prospects.
    Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
    Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
    [No Abstract]   [Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of theranostics in thoracic oncology.
    Filippov A; Bonjoc KC; Chea J; Bowles N; Poku E; Chaudhry A
    J Thorac Dis; 2020 Sep; 12(9):5140-5146. PubMed ID: 33145091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Pharmacokinetics and Dosimetry Studies of
    Marsh IR; Grudzinski J; Baiu DC; Besemer A; Hernandez R; Jeffery JJ; Weichert JP; Otto M; Bednarz BP
    J Nucl Med; 2019 Oct; 60(10):1414-1420. PubMed ID: 30926646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects.
    Shah A; Dabhade A; Bharadia H; Parekh PS; Yadav MR; Chorawala MR
    Z Naturforsch C J Biosci; 2024 Sep; 79(9-10):235-266. PubMed ID: 38807355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Imaging and Therapy for Neuroendocrine Tumors.
    Desai H; Borges-Neto S; Wong TZ
    Curr Treat Options Oncol; 2019 Aug; 20(10):78. PubMed ID: 31468190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.
    Ullrich M; Bergmann R; Peitzsch M; Zenker EF; Cartellieri M; Bachmann M; Ehrhart-Bornstein M; Block NL; Schally AV; Eisenhofer G; Bornstein SR; Pietzsch J; Ziegler CG
    Theranostics; 2016; 6(5):650-65. PubMed ID: 27022413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies.
    Agrawal A; Rangarajan V; Shah S; Puranik A; Purandare N
    Br J Radiol; 2018 Nov; 91(1091):20180103. PubMed ID: 30048149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theranostics Using Antibodies and Antibody-Related Therapeutics.
    Moek KL; Giesen D; Kok IC; de Groot DJA; Jalving M; Fehrmann RSN; Lub-de Hooge MN; Brouwers AH; de Vries EGE
    J Nucl Med; 2017 Sep; 58(Suppl 2):83S-90S. PubMed ID: 28864618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.
    Notni J; Wester HJ
    J Labelled Comp Radiopharm; 2018 Mar; 61(3):141-153. PubMed ID: 29143368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future.
    Echavidre W; Fagret D; Faraggi M; Picco V; Montemagno C
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bench-to-Bedside Theranostics in Nuclear Medicine.
    Jokar N; Assadi M; Yordanova A; Ahmadzadehfar H
    Curr Pharm Des; 2020; 26(31):3804-3811. PubMed ID: 32067609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostics in Oncology-Thriving, Now More than Ever.
    Werner RA; Higuchi T; Pomper MG; Rowe SP
    Diagnostics (Basel); 2021 Apr; 11(5):. PubMed ID: 33946670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Medicine in Pediatric and Adolescent Tumors.
    Kiratli PÖ; Tuncel M; Bar-Sever Z
    Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.